Clinical Trial Update: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial [Phase 2]

View source ↗

Summary

A National Cancer Institute–sponsored Phase 2 trial (NORM) is evaluating rituximab versus mosunetuzumab in nodular lymphocyte-predominant lymphomas, with recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodular Lymphocyte Predominant B-cell Lymphoma
• Nodular Lymphocyte-predominant Hodgkin Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | Status: RECRUITING